Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$45.56

-2.5 (-5.20%)

, GSK

GlaxoSmithKline

$38.90

-0.63 (-1.59%)

07:04
08/11/17
08/11
07:04
08/11/17
07:04

Ionis Pharmaceuticals retains all rights to inotersen, IONIS-FB-L

Ionis Pharmaceuticals (IONS) reported that the company has retained all rights to inotersen and IONIS-FB-L. As part of a reprioritization of its pipeline and strategic review of its Rare Diseases business, GSK (GSK) declined its options on both drugs. Ionis plans to file for marketing authorization for inotersen this year to support a commercial launch of inotersen in 2018. Inotersen is a drug designed to treat patients with TTR amyloidosis. The first indication Ionis is pursuing for inotersen is to treat patients with polyneuropathy due to hereditary TTR amyloidosis. Ionis completed the Phase 3 NEURO-TTR study of inotersen in which the drug demonstrated significant benefit on both primary clinical endpoints of neurological disease progression and quality of life in patients with hATTR-PN.

IONS

Ionis Pharmaceuticals

$45.56

-2.5 (-5.20%)

GSK

GlaxoSmithKline

$38.90

-0.63 (-1.59%)

  • 24

    Oct

IONS Ionis Pharmaceuticals
$45.56

-2.5 (-5.20%)

07/25/17
NEED
07/25/17
NO CHANGE
NEED
Ionis selloff a buying opportunity, says Needham
Needham analyst Chad Messer recommends using today's selloff in shares of Ionis Pharmaceuticals (IONS) as a buying opportunity. He believes concerns over the sustainability of Biogen's (BIIB) Spinraza launch overlook the longer term opportunity. The analyst has Buy rating on Ionis shares, which are down 11% in midday trading to $53.16.
07/25/17
WELS
07/25/17
NO CHANGE
Target $75
WELS
Outperform
Ionis challenges to Spinraza dosing addressable, says Wells Fargo
Wells Fargo analyst Jim Birchenough noted that Ionis (IONS) partner Biogen (BIIB) made comments that suggested slowing growth for Spinraza in the future due to technical challenges to dosing in patients with spinal surgeries. However, he understands that Ionis has seen initial success in dosing patients with type 2 SMA and spinal surgery and believes these patients will be viable candidates for Spinraza even though the process is more involved. Birchenough, who thinks the drug's impressive growth and broadening use and reimbursement more than offsets a hurdle dosing certain patients, raised his price target on Ionis shares to $75 and keeps an Outperform rating on the stock.
07/26/17
BMOC
07/26/17
NO CHANGE
BMOC
Ionis Pharmaceuticals should be bought on weakness, says BMO Capital
BMO Capital analyst Do Kim recommends buying Ionis on weakness following Biogen's comments on Spinraza. The analyst thinks that Spinraza can grow in Type and Type 3. Kim keeps an Outperform rating on Ionis.
07/27/17
BERN
07/27/17
INITIATION
BERN
Market Perform
Ionis Pharmaceuticals initiated with a Market Perform at Bernstein
Bernstein analyst Vincent Chen started coverage of Ionis with a $57 price target and a Market Perform rating.
GSK GlaxoSmithKline
$38.90

-0.63 (-1.59%)

06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/05/17
SBSH
07/05/17
DOWNGRADE
SBSH
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at Citi
Citi analyst Andrew Baum downgraded GlaxoSmithKline (GSK) to Neutral and lowered his price target for the shares to GBP 17 from GBP 18. The analyst believes the market is underappreciating the slowing of the company's HIV market growth. He prefers shares of AstraZeneca (AZN), Roche (RHHBY) and Bayer (BAYRY) for exposure to Europe.
07/05/17
07/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Capital One (COF) downgraded to Underperform from Neutral at Wedbush with analyst Henry Coffey saying ROE from operations is much lower than expected, and return on capital measures are sub-optimal. 2. Weyerhaeuser (WY) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos saying his thesis has played out and catalysts are limited in the intermediate term. 3. Buffalo Wild Wings (BWLD) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh saying the proxy fight and management shake-up has created uncertainty regarding the company's future and said a downward revision to guidance is likely due to continued margin pressures, soft topline trends, and lack of near-term catalysts. 4. GlaxoSmithKline (GSK) downgraded to Neutral from Buy at Citi with analyst Andrew Baum saying he believes the market is under-appreciating the slowing of the company's HIV market growth. 5. Oneok (OKE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Tom Abrams saying risk/reward is balanced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $5
PIPR
Neutral
OncoMed termination from GSK not surprising, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes GlaxoSmithKline (GSK) terminating its agreement with OncoMed Pharmaceuticals (OMED) is not surprising since tarextumab, the only remaining asset under the collaboration, failed previously to meet the primary endpoint in a Phase II study for first-line small cell lung cancer. The analyst says he remains focused on OncoMed's early stage pipeline including navicixizumab, rosmantuzumab and I/O assets anti-TIGIT and GITR trimer. Tenthoff keeps a Neutral rating on OncoMed with a $5 price target.

TODAY'S FREE FLY STORIES

EEM

MSCI Emerging Markets Index

$47.81

0.12 (0.25%)

06:16
11/24/17
11/24
06:16
11/24/17
06:16
Technical Analysis
MSCI Emerging Markets Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$51.43

0.4 (0.78%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPYYY

Centrica

$8.66

0.18 (2.12%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Upgrade
Centrica rating change  »

Centrica upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$50.43

0.39 (0.78%)

, CBS

CBS

$56.24

-0.5 (-0.88%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Hot Stocks
Dish reaches multi-year carriage agreement with CBS, terms not disclosed »

DISH Network (DISH) has…

DISH

Dish

$50.43

0.39 (0.78%)

CBS

CBS

$56.24

-0.5 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$24.24

-0.19 (-0.78%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$22.23

0.1881 (0.85%)

06:13
11/24/17
11/24
06:13
11/24/17
06:13
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$13.48

0.15 (1.13%)

06:10
11/24/17
11/24
06:10
11/24/17
06:10
Periodicals
Teva to slash up to 25% of Israeli workforce, Bloomberg reports »

Teva intends to cut as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

November PMI Composite…

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/22 Fed Balance…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/24…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/13 Money…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

November PMI Composite…

02:45
11/24/17
11/24
02:45
11/24/17
02:45
General news
FX Update: The dollar has managed to find a footing »

FX Update: The dollar…

10:30
11/23/17
11/23
10:30
11/23/17
10:30
General news
FX Action: EUR-USD, USD-JPY and other major pairings are in sideways mode »

FX Action: EUR-USD,…

DE

Deere

$145.25

6.02 (4.32%)

09:53
11/23/17
11/23
09:53
11/23/17
09:53
Upgrade
Deutsche Bank gets off sidelines, upgrades Deere shares to Buy »

Deutsche Bank analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

08:55
11/23/17
11/23
08:55
11/23/17
08:55
General news
FX Update: USD-CAD vaulted upwards on weak Canadian data »

FX Update: USD-CAD…

08:30
11/23/17
11/23
08:30
11/23/17
08:30
General news
FX Action: The USD index (DXY) logged a one-month low »

FX Action: The USD index…

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:08
11/23/17
11/23
08:08
11/23/17
08:08
Hot Stocks
Tesla CEO highlights 'record time' on Australian ion battery »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:07
11/23/17
11/23
08:07
11/23/17
08:07
Hot Stocks
Tesla completes construction on largest lithium ion battery in Australia »

The South Australian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

, INVA

Innoviva

$13.42

0.01 (0.07%)

07:56
11/23/17
11/23
07:56
11/23/17
07:56
Hot Stocks
GSK, Innoviva submit data to FDA for expanded Trelegy Ellipta label »

GlaxoSmithKline (GSK) and…

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

INVA

Innoviva

$13.42

0.01 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVM

Silvercorp Metals

$2.51

-0.07 (-2.71%)

07:52
11/23/17
11/23
07:52
11/23/17
07:52
Hot Stocks
Silvercorp Metals to buy back up to 5% of shares »

Silvercorp Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$10.00

-0.1 (-0.99%)

07:49
11/23/17
11/23
07:49
11/23/17
07:49
Hot Stocks
Cellcom Israel now second layer company according to Concentration Law »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.